Background: Ovarian cancer is with the greatest fatality rate in the gynecological malignancy, with about two-thirds of patients receiving an advanced diagnosis because of late presentation. Additionally, 90% of patients experience recurrence and eventually develop chemo resistance. Finding new prognostic indicators and treatment targets tailored to that cancer is therefore highly desirable. It was discovered that FOX A1 plays a part in the growth and development of numerous tumours, including gliomas, breast, stomach, lung, and esophageal cancers, although its function in ovarian cancer has not been fully characterised. Aim: To assess the value of FOX A1 immunohistochemical expression in epithelial ovarian cancer and its relationship with clinicopathologic features. Materials and methods: This is a retrospective cohort study that was carried out in the Pathology department, Faculty of Medicine, Zagazig University, in the period from November 2021 – to November 2022. All cases of epithelial ovarian cancer of different; grades, stages and histopathological subtypes with complete clinical data were included in the study. Specimens of paraffin blocks were obtained by total abdominal hysterectomy with bilateral salpingoophorectomy (TAH+BSO) with omentectomy and lymph node dissection. They were examined by two independent pathologist for evaluation grade and stage. FOX A1 immunohistochemical staining was done for all specimens. Results: There was a statistically significant association betweenFOX A1 expression and patients' age, menopause, patients with bilateral lesions, ruptured capsule, positive peritoneal cytology, lymph node metastasis, omental depositspathological grade and FIGO stage.- Conclusion: FOX A1 expression was related to poor prognostic predictors in EOC.